The U.S. Drug Enforcement Administration (DEA) and the Department of Health and Human Services (HHS) have issued a fourth temporary extension[1] (the “Fourth Temporary Extension”) of rules that allow providers to prescribe controlled substances via telemedicine without an initial in-person exam through December 31, 2026. These rules, first introduced during the COVID-19 public health emergency,…
The Medication Access and Training Expansion (“MATE”) Act was signed into law on December 29, 2022. The Act applies to all “qualified practitioners” anticipating initial or renewal DEA registration on or after June 27, 2023. A qualified practitioner is someone licensed under state law to prescribe controlled substances (excluding veterinarians). As part of the DEA…
The materials provided in this website are for informational purposes only and are not for the purpose of providing legal advice. Transmission of information from the ML website is not intended to create, and its receipt by you does not create an attorney-client relationship with ML or any of its individual attorneys or personnel.
If you elect to communicate with anyone at ML through this website, or otherwise, in connection with a matter for which we do not already represent you, your communication can not be treated as privileged or confidential. Do not transmit any information about any matter (and particularly not information you regard as confidential) that may involve you until ML has agreed to represent you, and you have received confirmation of that fact in the form of a written engagement letter.